What’s the current market cap for Capricor stock?

Capricor (CAPR) has a market cap of $1.5bn as of June 16, 2026.

What is the P/E ratio for Capricor stock?

The price to earnings (P/E) ratio for Capricor (CAPR) stock is 0 as of June 16, 2026.

Does Capricor stock pay dividends?

No, Capricor (CAPR) stock does not pay dividends to its shareholders as of June 16, 2026.

When is the next Capricor dividend payment date?

Capricor (CAPR) stock does not pay dividends to its shareholders.

What is the beta indicator for Capricor?

Capricor (CAPR) has a beta rating of 0.48. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy Capricor stock | $CAPR Share Price

13:30

15:10

16:45

18:25

20:00

About Capricor

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

Ticker

$CAPR

Sector

Health

Primary listing

NASDAQ

Employees

231

Headquarters

San Diego, United States

Website

www.capricor.com

Capricor Metrics

BasicAdvanced

$1.5bn

-$2.32

0.48

What the Analysts think about Capricor

Analyst ratings (Buy, Hold, Sell) for Capricor stock.

Bulls say / Bears say

Capricor’s pivotal Phase 3 HOPE-3 trial met its primary endpoint by demonstrating statistically and clinically significant preservation of left ventricular ejection fraction in Duchenne muscular dystrophy patients (Reuters)

Capricor entered into an exclusive commercialization and distribution agreement with Nippon Shinyaku for Deramiocel in the United States and Japan, securing key strategic partners ahead of regulatory approval (Capricor)

Capricor ended 2025 with $318.1 million in cash, cash equivalents and marketable securities, more than doubling its year-end 2024 balance and extending its cash runway into 2027 (Nasdaq)

The FDA accepted Capricor’s Class 2 BLA resubmission for Deramiocel and set a PDUFA target action date of August 22, 2026, meaning a final approval decision remains several months away (Capricor)

Capricor reported zero revenue and a net loss of $33.9 million in Q1 2026, with operating expenses rising to $36.8 million year-over-year, highlighting a high cash burn rate absent commercial sales (Capricor)

On May 7, 2026, Capricor filed suit against Nippon Shinyaku and NS Pharma seeking rescission of its U.S. distribution agreement for Deramiocel, potentially distracting management and delaying commercialization efforts (Capricor)

Data summarised monthly by Lightyear AI. Last updated on 25 May 2026.

Capricor Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

Capricor Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $CAPR

Capital at risk

Market closed

Upcoming events

No upcoming events

Bulls say / Bears say

Capricor ended 2025 with $318.1 million in cash, cash equivalents and marketable securities, more than doubling its year-end 2024 balance and extending its cash runway into 2027 (Nasdaq)

The FDA accepted Capricor’s Class 2 BLA resubmission for Deramiocel and set a PDUFA target action date of August 22, 2026, meaning a final approval decision remains several months away (Capricor)

Data summarised monthly by Lightyear AI. Last updated on 25 May 2026.